• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=7627932).
  

PubMed=1995877; DOI=10.1021/jm00106a013
Farquhar D., Newman R.A., Zuckerman J.E., Andersson B.S.
Doxorubicin analogues incorporating chemically reactive substituents.
J. Med. Chem. 34:561-564(1991)

PubMed=1568450
Andersson B.S., Bergerheim U.S.R., Collins V.P., Childs C., Beran M., Sen S., Arden K.C., Pathak S., Siciliano M.J., Ost A., Freireich E.J.
KBM-3, an in vitro model of human acute myelomonocytic leukemia.
Exp. Hematol. 20:361-367(1992)

PubMed=7627932; DOI=10.1016/0165-4608(94)00282-g
Sen S., Zhou H.-Y., Andersson B.S., Cork A., Freireich E.J., Stass S.A.
p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro.
Cancer Genet. Cytogenet. 82:35-40(1995)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)